SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens-Reference-Cited by-同舟云学术

SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens

Published:2021-05-29 Issue:14 Volume:117 Page:2702-2704
ISSN:0008-6363
Container-title:Cardiovascular Research
language:en
Short-container-title:

Author:

Chung Yu Jin¹^ORCID,Park Kyung Chan²^ORCID,Tokar Sergiy³^ORCID,Eykyn Thomas R¹³^ORCID,Fuller William⁴^ORCID,Pavlovic Davor⁵^ORCID,Swietach Pawel²^ORCID,Shattock Michael J¹^ORCID

Affiliation:

1. British Heart Foundation Centre of Research Excellence, King’s College London, UK

2. Burdon Sanderson Cardiac Science Centre, Department of Anatomy, Physiology and Genetics, University of Oxford, Oxford, UK

3. School of Biomedical Engineering and Imaging Sciences, King’s College London, UK

4. Institute of Cardiovascular & Medical Sciences, University of Glasgow, UK

5. Institute for Cardiovascular Sciences, University of Birmingham, UK

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

http://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvab184/39312412/cvab184.pdf

Reference12 articles.

1. Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart;Chung;Cardiovasc Res,2021

2. SGLT2 inhibitor Empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions;Zuurbier;Cardiovasc Res,2021

3. Does the cardioprotective effect of Empagliflozin involve inhibition of the sodium-proton exchanger?;Murphy;Cardiovasc Res,2021

4. Pseudoreplication in physiology: more means less;Eisner;J Gen Physiol,2021

5. S0859, an N-cyanosulphonamide inhibitor of sodium-bicarbonate cotransport in the heart;Ch'en;Br J Pharmacol,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors;Cardiovascular Research;2024-01-18

2. mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy;International Journal of Molecular Sciences;2023-10-11

3. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction;European Heart Journal;2023-09-07

4. Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level;Pharmaceutics;2023-06-08

5. Analysis of the cardiac effects of sodium-glucose co-transporter 2 inhibitors in animals without diabetes and a clinical perspective;European Journal of Pharmacology;2023-04